GLP-1 Peptides: New Frontiers in 2025

Key Takeaways

A Journal of the Endocrine Society review found that GLP-1 and GIP receptor gene polymorphisms may influence how individual patients respond to incretin therapies in clinical and preclinical models.
A multi-target trial emulation study in BMJ Open observed an association between GLP-1 receptor agonist use and fewer alcohol-related hospitalizations among adults with alcohol use disorder.
A Biological Psychiatry review summarized preclinical and early human evidence suggesting GLP-1 receptor agonists may reduce opioid-seeking behavior, from rat models through preliminary human data.
A multicenter U.S. cohort study in Frontiers in Endocrinology found tirzepatide was associated with a reduced risk of pulmonary embolism and deep vein thrombosis compared with controls.
A Surgical Endoscopy analysis documented measurable declines in certain bariatric surgery procedures coinciding with the rise of semaglutide and tirzepatide prescribing.

Why GLP-1 Research Is Accelerating in 2025

GLP-1 research is accelerating in 2025 because the therapeutic scope of these peptides continues to expand well beyond their original metabolic indications—and mechanistic and population-level evidence is now supporting that expansion. What began as a glucose-lowering agent class has generated credible signals across addiction medicine, thrombosis, urology, and surgical practice within a few years, compelling researchers across specialties to investigate.

The breadth of emerging evidence is striking:

Addiction medicine: A multi-target trial emulation study found an association between GLP-1 receptor agonist use and reduced alcohol-related hospitalizations in adults with alcohol use disorder (observational data), drawing psychiatry and addiction researchers into a field previously dominated by endocrinologists. A review bridging rat models to early human data examined GLP-1 receptor agonists as candidate treatments for opioid use disorder (preclinical and early clinical evidence), showing how laboratory signals are motivating translational work.
Thrombosis risk: A multicenter U.S. cohort study reported that tirzepatide was associated with reduced risk of pulmonary embolism and deep vein thrombosis (observational data). If confirmed in prospective trials, this signal would represent a cardiovascular benefit independent of weight loss alone.
Urology: A systematic review examined GLP-1 receptor agonists alongside bariatric surgery for managing urological complications of morbid obesity, demonstrating evaluation in specialty areas distant from the class’s origins.
Surgical practice: A utilization study documented evolving patterns in bariatric surgery since semaglutide and tirzepatide became widely available (real-world data), showing that pharmacological options are actively competing with and complementing surgical approaches.

Researchers are also pursuing precision medicine questions. A study on fasting GLP-1 and GIP levels investigated whether baseline incretin concentrations predict initial response to semaglutide and tirzepatide (early clinical data), while a review of receptor polymorphisms explored whether genetic variation in GLP-1 and GIP receptors influences therapy outcomes (mechanistic evidence). Both reflect a field moving from population-level efficacy toward personalized frameworks.

The convergence of new indications, real-world utilization data, and personalization research explains the unusually dense wave of GLP-1 literature across disciplines in 2025.

Disclaimer: This section is for informational purposes only and does not constitute medical advice. All findings described are specific to the study models and populations cited. Consult a qualified healthcare professional for any medical decisions.

Genetics May Shape Who Responds—and How

Genetic variation in GLP-1 and GIP receptors appears to meaningfully influence how individual patients respond to incretin-based peptide therapies, according to emerging pharmacogenomic evidence. Two people taking the same drug at the same dose may experience substantially different outcomes—not because of lifestyle or adherence, but because of inherited differences in the proteins these peptides target.

A 2025 review in Personalization of Incretin Therapy examined how single-nucleotide polymorphisms (SNPs) in the GLP1R and GIPR genes may alter receptor signaling, downstream metabolic effects, and clinical response to agents like semaglutide and tirzepatide (preclinical and clinical contexts). The authors found that specific variants have been associated with differential glycemic responses and weight-loss outcomes. However, they note the field remains early-stage, and replication across diverse populations is still needed.

Key findings include:

Receptor-level variation: Polymorphisms in GLP1R can alter how efficiently the receptor couples to intracellular signaling pathways, potentially blunting or amplifying the glucose-lowering and appetite-suppressing effects of GLP-1 receptor agonists in carriers of certain variants (preclinical and clinical evidence).
Dual-agonist complexity: Because tirzepatide targets both GLP-1 and GIP receptors, patients with loss-of-function or reduced-function variants in GIPR may respond differently to tirzepatide than to a selective GLP-1 agonist like semaglutide—a distinction that could eventually inform prescribing decisions.
Baseline hormone levels as a predictor: A separate clinical study investigated whether fasting GLP-1 and GIP levels—partly a reflection of underlying physiology shaped by genetics—could predict initial response to semaglutide and tirzepatide. Baseline incretin tone may carry predictive signal, though the authors caution that larger prospective studies are required before clinical application.

These findings point toward a future in which receptor genotyping and baseline hormone profiling might help stratify patients before therapy begins. The incretin personalization review frames pharmacogenomics as a plausible path toward precision prescribing—while acknowledging that validated clinical algorithms do not yet exist.

For now, research remains largely observational and mechanistic. No genetic test has been approved or validated to guide incretin therapy selection in routine care.

Disclaimer: This section is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

Addiction Medicine Finds a New Area of Interest

Addiction medicine researchers are actively investigating GLP-1 receptor agonists as potential treatments for alcohol use disorder and opioid use disorder—two of the most treatment-resistant conditions in modern medicine. Early human and preclinical data suggest these metabolic peptides may reduce addictive behavior through shared neurobiological pathways, though evidence remains preliminary.

The alcohol use disorder signal is the most clinically immediate. A multi-target trial emulation study of real-world data found a statistically significant association between GLP-1 receptor agonist use and reduced alcohol-related hospitalizations among adults with alcohol use disorder. Because this was an observational, emulated trial design rather than a randomized controlled trial, causality cannot be established—but the magnitude and consistency of the association across multiple analytical targets has drawn serious attention from addiction specialists.

The opioid use disorder question follows a different evidentiary path. A translational review tracing evidence from rodent models to early human data outlines the mechanistic rationale:

In animal models, GLP-1 receptor agonists reduced opioid self-administration and attenuated opioid-induced reward signaling in mesolimbic circuits
The proposed mechanism centers on GLP-1 receptors expressed in dopaminergic reward regions, including the ventral tegmental area and nucleus accumbens
Early human data referenced in the review are preliminary and insufficient to establish clinical efficacy, but directionally consistent with preclinical findings

The research is scientifically plausible because the reward-suppressing effects observed in obesity—where GLP-1 agonists are already approved—appear to engage circuitry shared with substance-related reward processing. Researchers hypothesize that the dopaminergic dampening that reduces compulsive eating may generalize to drug-seeking behavior, though this remains a hypothesis requiring prospective clinical validation.

Several caveats apply. Neither semaglutide nor tirzepatide is approved for any addiction indication. The observational alcohol data cannot rule out confounding—patients prescribed GLP-1 agonists may differ systematically from those who are not. The translational gap between rodent opioid models and human opioid use disorder is historically wide. Addiction medicine’s interest in this drug class is scientifically grounded, but the field remains in early hypothesis-testing stages.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider regarding any medical condition or treatment decision.

Cardiovascular and Urological Signals Emerge

Early evidence from observational and review-level research suggests that GLP-1 receptor agonists — and tirzepatide in particular — are generating meaningful signals in both cardiovascular and urological domains, extending their research profile well beyond glycemic and weight outcomes.

Cardiovascular signals

A multicenter U.S. cohort study examined tirzepatide’s association with venous thromboembolic events in a real-world population. Investigators found that tirzepatide use was associated with a reduced risk of both pulmonary embolism and deep vein thrombosis compared with control groups in that observational dataset (multicenter cohort study). Because this is an observational design, confounding cannot be ruled out, and no causal claim is established. The signal is nonetheless notable given that obesity itself is a well-recognized risk factor for venous thromboembolism.

Urological signals

A recent systematic review evaluated the urological complications of morbid obesity and assessed the potential role of both bariatric surgery and GLP-1 receptor agonists in managing those complications (systematic review). Key urological conditions examined included:

Urinary incontinence — linked to obesity-related intra-abdominal pressure, with weight loss interventions showing improvement signals
Urolithiasis (kidney stones) — metabolic changes from obesity and from weight-loss interventions both influence stone risk profiles
Lower urinary tract symptoms — associated with adiposity and potentially modifiable through weight reduction

The review found that GLP-1 receptor agonist use was associated with improvements in several of these conditions in the synthesized studies. However, the authors noted that the evidence base remains limited in size and methodological rigor, and longer-term urological outcome data are largely absent (systematic review).

Implications

These two lines of evidence — one observational, one review-based — illustrate how GLP-1 and dual GIP/GLP-1 receptor agonists are being scrutinized across organ systems that were not primary targets in their original development programs. Researchers caution that neither cardiovascular nor urological findings are yet at the level of evidence required to inform clinical practice guidelines. Dedicated prospective trials in these domains are needed before conclusions can be drawn.

Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment guidance. Consult a qualified healthcare professional before making any medical decisions.

Bariatric Surgery Trends Shift as Peptides Rise

Bariatric surgery volumes in the United States have declined measurably since semaglutide and tirzepatide became widely available, according to a 2025 utilization study — though the surgical field is adapting rather than retreating. The same study found that patients still pursuing surgery increasingly represent those with more severe metabolic disease or inadequate response to pharmacotherapy, a shift in case complexity that surgeons and health systems are beginning to address.

Several dynamics are driving this realignment:

**Pharmacological reach is expanding. **** GLP-1 receptor agonists and dual agonists like tirzepatide are being studied across a widening range of obesity-related conditions. A systematic review on urological complications found that both bariatric surgery and GLP-1 receptor agonists show potential for managing obesity-linked urological conditions in preclinical and clinical evidence reviewed, framing the two approaches as complementary rather than strictly competitive.
Cardiovascular risk reduction is a differentiating signal. A multicenter U.S. cohort study found tirzepatide was associated with reduced risk of pulmonary embolism and deep vein thrombosis — complications historically cited as surgical risks — adding a dimension to the pharmacotherapy-versus-surgery calculus that clinicians are actively examining.
Response variability complicates head-to-head comparisons. Not all patients respond equally to incretin-based therapies. ** Research into GLP-1 and GIP receptor polymorphisms suggests genetic variation may influence individual pharmacological response, potentially explaining why some patients seek surgery after inadequate peptide therapy results. ** ** A separate study examining fasting GLP-1 and GIP hormone levels as predictors of initial drug response found that baseline incretin levels did not reliably forecast early outcomes with semaglutide or tirzepatide — underscoring that patient selection for either approach remains an open scientific question.

The picture emerging from current research is one of coexistence under pressure: bariatric surgery is not disappearing, but its role is being redefined as peptide-based therapies accumulate evidence across metabolic, cardiovascular, and behavioral health indications.

Disclaimer: This section is for informational purposes only and does not constitute medical advice. Findings described are specific to the study models and populations cited and should not be interpreted as guidance on treatment decisions.

Tolerability Nuances: A Hypersensitivity Case and Biomarker Questions

A published case report documents a clinically confirmed hypersensitivity reaction to tirzepatide that resolved upon switching to semaglutide — suggesting that allergic responses to dual GIP/GLP-1 receptor agonists do not necessarily preclude tolerance to GLP-1–only agents. This pattern carries practical implications for how clinicians might sequence incretin therapies when adverse immune responses arise.

The 2025 case report described a patient who developed a hypersensitivity reaction to tirzepatide. Upon discontinuation and transition to semaglutide, the patient demonstrated tolerance — a finding the authors interpreted as evidence that the reaction was specific to tirzepatide rather than a class-wide incretin sensitivity. Because tirzepatide engages both GIP and GLP-1 receptors while semaglutide targets only GLP-1 receptors, the case raises a mechanistic question: whether GIP receptor agonism, the tirzepatide molecular scaffold, or formulation excipients drove the immune response. The report does not resolve this question but documents the clinical observation as a data point.

Separately, emerging research is examining whether baseline biomarkers can predict initial response to these agents — a question relevant to tolerability planning. A recent study on fasting incretin levels investigated whether pre-treatment fasting GLP-1 and GIP concentrations predict pharmacological response to semaglutide and tirzepatide. The findings suggest that baseline incretin hormone levels may carry a predictive signal. However, the study was limited to early pharmacological response rather than long-term outcomes or adverse event risk.

Genetic variation adds another layer. A review of incretin receptor polymorphisms examined how variants in GLP-1 and GIP receptor genes might influence therapy response, noting that receptor-level genetic differences could plausibly affect both efficacy and tolerability across individuals. Key findings include:

GLP-1R and GIPR polymorphisms have been associated with variable glycemic and weight responses in preclinical and clinical data reviewed therein
The authors frame personalization of incretin therapy as an open research question, not a clinical standard
No validated biomarker panel currently exists to stratify patients by hypersensitivity risk prospectively

These three lines of evidence — a documented cross-agent tolerability case, fasting biomarker research, and receptor genetics — outline an emerging field still building its predictive toolkit. None of the findings reviewed here constitute clinical guidance.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional regarding any medical decisions.

FAQ

What are GLP-1 receptor agonists and why are researchers studying them so broadly?

GLP-1 receptor agonists are peptide-based drugs that mimic the gut hormone glucagon-like peptide-1. Because GLP-1 receptors are found in the brain, gut, heart, and other tissues, researchers are investigating whether activating them produces effects beyond glucose control and weight loss—including in addiction, clotting, and urological health. All findings cited here come from specific study models and do not constitute medical advice.

What did the genetics study find about personalized incretin therapy?

A review published in the Journal of the Endocrine Society examined whether polymorphisms in GLP-1 and GIP receptor genes could influence therapeutic response to incretin-based drugs. The authors concluded that genetic variation may be a relevant factor in predicting outcomes. However, they noted the evidence base is still developing, and further research is needed before clinical application.

What did researchers find about GLP-1 drugs and alcohol use disorder?

A multi-target trial emulation study published in BMJ Open found an association between GLP-1 receptor agonist use and a lower rate of alcohol-related hospitalizations among adults diagnosed with alcohol use disorder. The observational design means causation cannot be established, and the authors called for randomized controlled trials to confirm the signal.

Is there evidence linking GLP-1 receptor agonists to opioid use disorder?

A review in Biological Psychiatry summarized a body of evidence ranging from rat models—where GLP-1 receptor agonists reduced opioid self-administration—to preliminary human data suggesting possible reductions in opioid craving or use. The authors described the evidence as promising but early, emphasizing that robust human clinical trials are still needed.

What did the tirzepatide and blood clot study show?

A multicenter U.S. cohort study published in Frontiers in Endocrinology found that patients receiving tirzepatide had a statistically lower observed risk of pulmonary embolism and deep vein thrombosis compared with a control group. As an observational cohort study, it cannot prove causation, and the authors noted that confounding factors may have influenced results.

How are semaglutide and tirzepatide affecting bariatric surgery rates?

An analysis published in Surgical Endoscopy tracked bariatric surgery utilization over time and found measurable changes in procedure volumes that coincided with the broader prescribing uptake of semaglutide and tirzepatide. The study did not establish that the drugs directly caused the decline, and the authors noted that patient selection, insurance coverage, and other factors also play roles.

Note: This article is for general information and is not medical advice. Talk to a licensed clinician before using any peptide product.